Investment Analysts’ Weekly Ratings Changes for Apnimed (APMD)

Apnimed (NASDAQ: APMD) recently received a number of ratings updates from brokerages and research firms:

• 8/26/2026 – Apnimed was upgraded by Zacks Research to “hold”.
• 8/25/2026 – Apnimed is now covered by Evercore Inc. They set an “outperform” rating on the stock.
• 8/25/2026 – Apnimed is now covered by Lifesci Capital. They set an “outperform” rating and a $50.00 price target on the stock.
• 8/25/2026 – Apnimed is now covered by Bank of America Corporation. They set a “buy” rating and a $41.00 price target on the stock.
• 8/25/2026 – Apnimed is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $60.00 price target on the stock.
• 8/8/2026 – Apnimed was upgraded by Wall Street Zen to “hold”.

Insider Buying and Selling at Apnimed

In other Apnimed news, major shareholder Morningside Venture Investment acquired 312,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the insider directly owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. This trade represents a 4.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.